The three pathways of activation all generate homologous variants of the protease C3-convertase. The classical complement pathway typically requires antigen—antibody complexes (immune complexes) for ...

BCX9930, an Oral Factor D Inhibitor, Suppresses Complement Alternative Pathway C3 Convertase Activity in vitro, and in Patients with Complement 3 Glomerulopathy (Poster #80); Sunday, August 28 ...

Inhibitors of proximal and terminal complement cascades can often control red-cell hemolysis associated with paroxysmal nocturnal hemoglobinuria, but some patients have breakthrough hemolysis.